LY333531 treatment for symptomatic peripheral neuropathy in patients with diabetes
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Peripheral nervous system diseases
- Focus Registrational; Therapeutic Use
- 28 Jul 2006 Status change
- 23 Oct 2005 New trial record.